Back to top
more

Editas Medicine (EDIT)

(Delayed Data from NSDQ)

$3.19 USD

3.19
2,265,425

+0.23 (7.77%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $3.19 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Editas Medicine (EDIT) Enters Oversold Territory

Editas Medicine, Inc. (EDIT) has been on a bit of a cold streak lately

    Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?

    Is (EDIT) Outperforming Other Medical Stocks This Year?

      Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?

      Sector ETF report for ARKG

        Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia

        Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia

          Kevin Cook headshot

          CRISPR Science and Stocks: Knowing Enough to Invest

          Can you learn enough about the science and the companies to invest with confidence?

            Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?

            Is Editas Medicine, Inc. (EDIT) Outperforming Other Medical Stocks This Year?

              Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex

              Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex

                Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

                Is Editas Medicine, Inc. (EDIT) Outperforming Other Medical Stocks This Year?

                  Vertex/CRISPR's Sickle Disease Candidate Put on Hold by FDA

                  FDA places clinical hold on a Vertex (VRTX) and CRISPR Therapeutics' IND application for CTX001 for the treatment of sickle cell disease.

                    David Borun headshot

                    Should You Buy the Dip in CRISPR Therapeutics?

                    A "Clinical Hold" from the FDA has the shares falling, but is it an opportunity to get in?

                      David Borun headshot

                      Is Genome Editing the Next Biotech Breakthrough?

                      CRISPR technology is promising to be the foundation the treatment of 1000s of diseases

                        Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?

                        Is Editas Medicine, Inc. (EDIT) Outperforming Other Medical Stocks This Year?

                          Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics

                          Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics

                            Kevin Cook headshot

                            Why Sarepta (SRPT) Jumped and We Sold

                            Gains have rewarded the patient, but the long-term is balanced with obstacles still ahead in the FDA gauntlet

                              Kevin Cook headshot

                              Healthcare Heroes That Aren't Done Yet

                              Key growth stocks across medical industries tell you the megatrends are in full force for years to come

                                Editas Medicine (EDIT) Surges: Stock Moves 13.2% Higher

                                Editas Medicine (EDIT) was a big mover last session, as the company saw its shares rise more than 13% on the day amid huge volumes.

                                  Kevin Cook headshot

                                  Bitcoin or CRISPR: Which is the Bigger Disruptor?

                                  In just 5 years, two new "exponential technologies" have been created that will dramatically change the world

                                    What's in the Cards for Adverum (ADVM) This Earnings Season?

                                    Adverum Biotechnologies (ADVM) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

                                      Editas Medicine (EDIT) Looks Good: Stock Moves Up 11.3%

                                      Editas Medicine, Inc. (EDIT) moved big moved last session, as its shares rose over 11% on the day.

                                        What's in Store for Merck KGaA (MKGAF) in Q1 Earnings?

                                        Merck KGaA (MKGAF) is scheduled to report first-quarter 2017 earnings results on May 18.

                                          Why Editas Medicine (EDIT) Might Surprise This Earnings Season

                                          Investors are always looking for stocks that are poised to beat at earnings season and Editas Medicine, Inc. (EDIT) may be one such company.

                                            Perrigo Company (PRGO) Q1 Earnings: Disappointment in Store?

                                            Perrigo Company plc (PRGO) is expected to report first-quarter 2017 results later this month.

                                              4 Drug Stocks Poised to Beat this Earnings Season

                                              M&A and licensing deals as well as drug pricing issues are expected to remain in focus in 2017.

                                                What's in Store for Immune Design (IMDZ) Stock in Q1 Earnings?

                                                Immune Design Corp (IMDZ) is expected to report first-quarter 2017 results on May 9.

                                                  What's in Store for BioDelivery (BDSI) this Earnings Season?

                                                  BioDelivery Sciences International, Inc. (BDSI) is expected to report first-quarter 2017 results later this month. Last quarter, the company???s loss was wider than expected.